Vertex Pharmaceuticals and Crinetics Pharmaceuticals announce Vertex will acquire Crinetics in a cash-and-stock transaction valued at about $10 billion, according to multiple reports. The deal includes a price of $85 per share for Crinetics, which represents a premium to Crinetics’ prior trading levels. The companies say the acquisition is intended to expand Vertex’s rare-disease and endocrinology pipeline by adding Crinetics-developed therapies, including drugs Palsonify and Atumelnant, which target rare endocrine conditions. Wall Street Journal coverage highlights Vertex’s expectation that the addition of these programs could support substantial revenue growth, citing a potential increase of up to $5 billion in annual revenue, based on company statements. STAT notes the transaction is part of a broader period of increased biotech mergers and acquisitions activity. The outlets collectively describe the transaction as a strategic move to bolster Vertex’s late-stage and commercial pipeline, while extending its presence in rare endocrine disorders through Crinetics’ research and product candidates.